Veracyte Inc (12V.SG)
Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
At close: 10:32AM CEST
| Previous Close | 17.90 |
| Open | 18.40 |
| Bid | 18.00 x 0 |
| Ask | 18.00 x 0 |
| Day's Range | 17.90 - 18.40 |
| 52 Week Range | 17.50 - 26.80 |
| Volume | |
| Avg. Volume | 2 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | May 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireVeracyte to Release First Quarter 2024 Financial Results on May 7, 2024
SOUTH SAN FRANCISCO, Calif., April 22, 2024--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2024 after the close of market on Tuesday, May 7, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Business WireNew Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
SOUTH SAN FRANCISCO, Calif., April 22, 2024--New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
Business WireVeracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
SOUTH SAN FRANCISCO, Calif., April 16, 2024--Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
© 2024 Yahoo. All rights reserved.